Reduction in costs, blood products, and operating time in patients undergoing open heart surgery

Archives of Surgery

Volumn 132, Issue 8, 1997, Pages 858-861

  Lazzara, Robert R ^a   Kidwell, Francis E ^a   Kraemer, Michael F ^a   Wood, James A ^a   Starr, Albert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ADULT; AGED; BLOOD; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; FEMALE; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; OPERATION DURATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030753214     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430320060009     Document Type: Conference Paper

References (12)

1. Bidstrup BP, Royston DM, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989;97:364-372.
2. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 1992; 54:1031-1038.
3. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg. 1994;107:543-553.
4. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs. 1995; 49:954-983.
5. Schönberger JPAM, Everts PAM, Ercan H, et al. Low-dose aprotinin In internal mammary artery bypass operations contributes to important blood saving. Ann Thorac Surg. 1992;54:1172-1176.
6. Liu B, Tengborn L, Larson G, et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg. 1995;59:1534-1540.
7. Levy JH, Pifarre R, Schaff HV, et al. A multicenter double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995;92:2236-2244.
8. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 1996;62:1659-1668.
9. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg. 1991;51:936-941.
10. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. J Thorac Cardiovasc Surg. 1993; 55:147-153.
11. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg. 1995;108:1164-1172.
12. Levy JH, Ramsay JG, Murkln J. Aprotinin reduces the incidence of strokes following cardiac surgery. Circulation. 1996;94(suppl):1-535.